ATM-Deficient Cancers Provide New Opportunities for Precision Oncology

Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes and , with many more potential applications under study and in clinical trials. Here, we discuss the potential for extending PA...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2020-03, Vol.12 (3), p.687
Hauptverfasser:	Jette, Nicholas R, Kumar, Mehul, Radhamani, Suraj, Arthur, Greydon, Goutam, Siddhartha, Yip, Steven, Kolinsky, Michael, Williams, Gareth J, Bose, Pinaki, Lees-Miller, Susan P
Format:	Artikel
Sprache:	eng
Schlagworte:	Ataxia BRCA1 protein BRCA2 protein Breast cancer Cancer therapies Cell cycle Cell death Clinical trials Colorectal cancer Cytotoxicity Defects Deoxyribonucleic acid DNA DNA damage DNA repair Genomes Kinases Lung cancer Lymphoma Mutation Oncology Ovarian cancer Pancreatic cancer Poly(ADP-ribose) polymerase Precision medicine Prostate Protein kinase Proteins Regulatory approval Review Ribose Roles Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!